By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Therapeutic vaccines > Sipuleucel-t > Sipuleucel-T Dosage
Therapeutic vaccines
https://themeditary.com/dosage-information/sipuleucel-t-dosage-8892.html

Sipuleucel-T Dosage

Drug Detail:Sipuleucel-t (Sipuleucel-t [ si-pu-loo-sel-tee ])

Drug Class: Therapeutic vaccines

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Prostate Cancer

3 complete doses given at approximately 2-week intervals; infuse drug intravenously over 60 minutes.

Comments:

  • Peripheral blood mononuclear cells from patients are obtained via the leukapheresis procedure, which should be performed approximately 3 days prior to each infusion.
  • Patients should be pre-medicated orally with acetaminophen and an antihistamine (such as diphenhydramine) approximately 30 minutes prior to administration to minimize potential acute infusion reactions.
  • The patient should be observed for acute infusion reactions for at least 30 minutes following each infusion.
  • The maximum dosing interval has not been established.
  • This drug is intended solely for autologous use.
  • This drug is for IV use only; a cell filter should not be used.

Use: Treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

If Acute Infusion Reactions Occur:

  • Interrupt or slow the infusion depending on the reaction severity, and administer appropriate medical treatment as needed.
  • An interrupted infusion should not be resumed if the infusion bag will be at room temperature for more than 3 hours.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:

  • The infusion should not be initiated until confirmation of product release is received from the manufacturer. The manufacturer will send the Final Product Disposition Notification form containing the patient identifiers, expiration date and time, and the disposition status (approved for infusion or rejected) to the infusion site.
  • The infusion must begin prior to the expiration date and time on the Final Product Disposition Notification form and product label; expired product should not be administered.
  • Before infusion, it should be confirmed that the patient's identity matches the patient identifiers on the infusion bag and the Final Product Disposition Notification form.
  • Infusion bags that leak, are damaged, or contain clumps after gentle manual mixing should not be administered.
  • Patients unable to receive a scheduled infusion need to undergo an additional leukapheresis procedure prior to continuing a treatment course.
  • A patient needs adequate peripheral venous access or a central venous catheter to accommodate the leukapheresis procedure and infusions of this drug.

Storage and Handling Requirements:
  • The infusion bag should be gently mixed and re-suspended manually to disperse small clumps of cellular material.
  • The infusion bag should remain in the insulated polyurethane container (which should not be removed from the shipping box), and the lid of the insulated container should not be opened until administration time.
  • Once the infusion bag is removed from the insulated container, it should remain at room temperature for no more than 3 hours.

General:
  • This drug consists of autologous peripheral blood mononuclear cells, including antigen presenting cells (APCs) that have been activated during a defined culture period with recombinant human protein PAP-GM-CSF, which consists of an antigen expressed in prostate cancer tissue (prostatic acid phosphatase/PAP) linked to an immune cell activator (granulocyte-macrophage colony-stimulating factor/GM-CSF).
  • This drug contains APCs, T cells, B cells, natural killer cells and other cells; the number of cells present and the cellular composition of each dose will vary as it is dependent on the composition of cells obtained from the leukapheresis procedure.
  • The potency of this drug is partly determined by measuring the increased expression of the CD54 molecule (ICAM-1) on the surface of APCs after culture with PAP-GM-CSF.
  • Each dose contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated Ringer's Injection.
  • There are no known instances of overdosage from either a single infusion or a full course of therapy.

Patient Advice:
  • If you have a central venous catheter, inform your healthcare provider if you have fevers or any swelling/redness around the catheter site because these symptoms could be signs of an infected catheter.
  • Let your healthcare provider know if you are taking immunosuppressive agents
Share this Article
Latest News
Medical News

Cholesterol: Daily cup of beans may lower levels, improve heart health

Jun 03, 2025
Aging and longevity: What role might coffee play?
Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by